<?xml version='1.0' encoding='utf-8'?>
<document id="28314990"><sentence text="An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism." /><sentence text="RO5323441 is a humanized anti-placental growth factor (PlGF) monoclonal antibody that has shown preclinical activity in several cancer models" /><sentence text=" The objective of this analysis is to examine the pharmacokinetic (PK) results from four Phase I studies that have been conducted with RO5323441 (n = 61) and to report an apparent drug-drug interaction observed when RO5323441 was administered in combination with bevacizumab"><entity charOffset="135-144" id="DDI-PubMed.28314990.s3.e0" text="RO5323441" /><entity charOffset="216-225" id="DDI-PubMed.28314990.s3.e1" text="RO5323441" /><entity charOffset="263-274" id="DDI-PubMed.28314990.s3.e2" text="bevacizumab" /><pair ddi="false" e1="DDI-PubMed.28314990.s3.e0" e2="DDI-PubMed.28314990.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28314990.s3.e0" e2="DDI-PubMed.28314990.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28314990.s3.e0" e2="DDI-PubMed.28314990.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28314990.s3.e1" e2="DDI-PubMed.28314990.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28314990.s3.e1" e2="DDI-PubMed.28314990.s3.e2" /></sentence><sentence text="" /><sentence text="The four Phase I studies were a multiple-ascending dose study in 23 patients with solid tumors (Study 1), an open-label study in seven patients with colorectal/ovarian cancer (Study 2), a sorafenib combination study in nine patients with hepatocellular carcinoma (Study 3), and a bevacizumab combination study in 22 patients with recurrent glioblastoma (Study 4)"><entity charOffset="188-197" id="DDI-PubMed.28314990.s5.e0" text="sorafenib" /></sentence><sentence text=" A two-compartment linear population PK model was developed from these four studies to characterize the PK of RO5323441 in patients with cancer" /><sentence text="" /><sentence text="The PK properties of RO5323441 were similar in the first three studies"><entity charOffset="21-30" id="DDI-PubMed.28314990.s8.e0" text="RO5323441" /></sentence><sentence text=" However, substantially higher RO5323441 exposures were observed in Study 4 when RO5323441 was administered in combination with bevacizumab"><entity charOffset="31-40" id="DDI-PubMed.28314990.s9.e0" text="RO5323441" /><entity charOffset="81-90" id="DDI-PubMed.28314990.s9.e1" text="RO5323441" /><entity charOffset="128-139" id="DDI-PubMed.28314990.s9.e2" text="bevacizumab" /><pair ddi="false" e1="DDI-PubMed.28314990.s9.e0" e2="DDI-PubMed.28314990.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28314990.s9.e0" e2="DDI-PubMed.28314990.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28314990.s9.e0" e2="DDI-PubMed.28314990.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28314990.s9.e1" e2="DDI-PubMed.28314990.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28314990.s9.e1" e2="DDI-PubMed.28314990.s9.e2" /></sentence><sentence text=" A linear two-compartmental population PK model indicated that the co-administration of bevacizumab would decrease the clearance of RO5323441 by 53%"><entity charOffset="132-141" id="DDI-PubMed.28314990.s10.e0" text="RO5323441" /></sentence><sentence text=" Clinical data suggested that the decrease in RO5323441 clearance was inversely associated with bevacizumab exposure" /><sentence text="" /><sentence text="The exact reason for the increase in RO5323441 exposure following bevacizumab co-administration is not currently known" /><sentence text=" One possibility is a drug-drug interaction via a target-trapping mechanism that is mediated by the vascular endothelial growth factor receptor-1 (VEGFR-1)" /><sentence text="" /></document>